uploads/2019/01/Graph-6-5-1.png

A Look at AbbVie’s Diversified Product Portfolio in Fiscal 2019

By

Updated

Venclexta revenue trends

In addition to Humira and Imbruvica, AbbVie (ABBV) is focused on strengthening the commercial position of other drugs such as Venclexta, Mavyret, and Orilissa.

In the fourth quarter of 2018, AbbVie reported Venclexta sales of $124 million, of which $90 million were earned from the US market and the remaining $34 million were earned from international markets. According to the company’s fourth-quarter earnings conference call, this performance was driven by solid uptake in the second-line setting for relapsed/refractory chronic lymphocytic leukemia (or CLL) patients.

In fiscal 2018, AbbVie reported Venclexta sales of $344 million, of which $247 million were earned from the US market and the remaining $97 million were earned from international markets. The company expects to report $750 million worth of Venclexta sales in fiscal 2019.

Article continues below advertisement

On June 11, 2018, Roche Holdings (RHHBY) and AbbVie announced FDA approval for its Venclexta-Rituxan regimen in relapsed/refractory CLL indication, based on its Phase 3 MURANO study. On November 21, 2018, Roche Holdings and AbbVie announced conditional FDA approval for Venclexta in front line acute myeloid leukemia indication for patients satisfying certain conditions.

HCV sales trajectory

In the fourth quarter of 2018, AbbVie reported hepatitis C (or HCV) product sales of $862 million, which is a YoY rise of 71.4% on an operational basis and 69.3% on a reported basis. According to the company’s fourth-quarter earnings conference call, this performance was driven by robust uptake of Mavyret, which currently accounts for a 50% share of the global HCV market. In the fourth quarter of 2018, AbbVie reported Mavyret sales of $819 million, of which $408 million were earned from the US market and the remaining $411 million were earned from international markets.

In fiscal 2018, AbbVie reported HCV product sales of $3.62 billion, of which $1.62 billion were earned from the US market and the remaining $2.0 billion were earned from international markets. The company expects to report $3.3 billion HCV product sales in fiscal 2019. According to the company’s fourth-quarter earnings conference call, AbbVie is expected to report flat revenue performance in the US market and $1.7 billion sales in the international markets for its HCV portfolio for fiscal 2019.

In the next article, we’ll discuss margin and expense trends for AbbVie in fiscal 2018.

Advertisement

More From Market Realist